Form 4 for UTHR UNITED THERAPEUTICS Corp
Accepted 2026-04-16 16:31:28 ET · period of report 2026-03-13 · accession 0001106578-26-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DTI | 2026-04-16 16:31 | 2026-03-13 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | S - Sale+OE | $536.95 | -75 | 324.4K | -0.0% | -$40.3K |
| DMT | 2026-04-16 16:31 | 2026-04-14+ | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $146.03 | +19.0K | 50.0K | +61% | +$2.77M |
| DMT | 2026-04-16 16:31 | 2026-04-14+ | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | S - Sale+OE | $579.86 | -19.0K | 40.5K | -32% | -$11.02M |
| DMT | 2026-04-16 16:31 | 2026-04-14+ | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $0.00 | -19.0K | 36.0K | -35% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-13 | S | D | 75 | $536.95 | 324,443 | I by Trust | — | — | (F1) This transaction was not reported earlier due to administrative error. (F2) Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| 2 | Common | Common Stock | 2026-04-14 | M | A | 9,500 | $146.03 | 50,013 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 3 | Common | Common Stock | 2026-04-14 | S | D | 280 | $574.25 | 49,733 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F4) This transaction was executed in multiple trades at prices ranging from $573.75 to $574.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-04-14 | S | D | 404 | $575.25 | 49,329 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F5) This transaction was executed in multiple trades at prices ranging from $574.75 to $575.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2026-04-14 | S | D | 80 | $575.89 | 49,249 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F6) This transaction was executed in multiple trades at prices ranging from $575.88 to $575.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2026-04-14 | S | D | 1,360 | $577.62 | 47,889 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F7) This transaction was executed in multiple trades at prices ranging from $577.00 to $577.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2026-04-14 | S | D | 1,164 | $578.41 | 46,725 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F8) This transaction was executed in multiple trades at prices ranging from $578.04 to $579.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 8 | Common | Common Stock | 2026-04-14 | S | D | 1,580 | $579.65 | 45,145 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F9) This transaction was executed in multiple trades at prices ranging from $579.09 to $580.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Common | Common Stock | 2026-04-14 | S | D | 3,675 | $580.55 | 41,470 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F10) This transaction was executed in multiple trades at prices ranging from $580.10 to $581.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 10 | Common | Common Stock | 2026-04-14 | S | D | 957 | $581.50 | 40,513 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F11) This transaction was executed in multiple trades at prices ranging from $581.12 to $581.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 11 | Common | Common Stock | 2026-04-15 | M | A | 9,500 | $146.03 | 50,013 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 12 | Common | Common Stock | 2026-04-15 | S | D | 80 | $575.29 | 49,933 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 13 | Common | Common Stock | 2026-04-15 | S | D | 880 | $576.98 | 49,053 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F12) This transaction was executed in multiple trades at prices ranging from $576.47 to $577.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 14 | Common | Common Stock | 2026-04-15 | S | D | 629 | $577.81 | 48,424 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F13) This transaction was executed in multiple trades at prices ranging from $577.56 to $578.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 15 | Common | Common Stock | 2026-04-15 | S | D | 684 | $579.14 | 47,740 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F14) This transaction was executed in multiple trades at prices ranging from $578.57 to $579.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 16 | Common | Common Stock | 2026-04-15 | S | D | 2,255 | $580.02 | 45,485 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F15) This transaction was executed in multiple trades at prices ranging from $579.57 to $580.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 17 | Common | Common Stock | 2026-04-15 | S | D | 2,819 | $581.05 | 42,666 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F16) This transaction was executed in multiple trades at prices ranging from $580.57 to $581.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 18 | Common | Common Stock | 2026-04-15 | S | D | 1,624 | $582.05 | 41,042 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F17) This transaction was executed in multiple trades at prices ranging from $581.57 to $582.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 19 | Common | Common Stock | 2026-04-15 | S | D | 202 | $583.41 | 40,840 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F18) This transaction was executed in multiple trades at prices ranging from $582.66 to $583.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 20 | Common | Common Stock | 2026-04-15 | S | D | 327 | $584.24 | 40,513 | D | — | — | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F19) This transaction was executed in multiple trades at prices ranging from $584.09 to $584.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 21 | Derivative | Stock Option | 2026-04-14 | M | D | 9,500 | $0.00 | 45,500 | D | $146.03 · 2020-03-15 to 2027-03-15 | 9,500 Common Stock | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 22 | Derivative | Stock Option | 2026-04-15 | M | D | 9,500 | $0.00 | 36,000 | D | $146.03 · 2020-03-15 to 2027-03-15 | 9,500 Common Stock | (F3) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |